Dopaminergic neural progenitor cell therapy （Sumitomo Dainippon Pharma）

多巴胺能神经祖细胞疗法（Sumitomo Dainippon Pharma）

Report date: 2023/01/12 16:09:00

Base Information

Drug NameDopaminergic neural progenitor cell therapy （Sumitomo Dainippon Pharma）
Drug Alias NameAllo iPS cell-derived dopamine neural progenitor (Sumitomo Dainippon)Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells (Sumitomo Dainippon)
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > iPSC-derivedCell and gene therapy > Cell therapy > Somatic cell > Dopaminergic neural orogenitor cell therapy
Mechanisms of ActionDopaminergic cell replacements
TargetsNot applicable
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSumitomo Dainippon Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Dainippon
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A